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Abstract
West Nile virus (WNV) is a neurovirulent single stranded RNA mosquito-borne flavivirus, whose main natural hosts are birds,
but it also infects humans and horses. Nowadays, no human vaccine is commercially available and clinical treatment is only
supportive. Recently, it has been shown that RNA transcripts, mimicking structural domains in the non-coding regions
(NCRs) of the foot-and mouth disease virus (FMDV) induce a potent IFN response and antiviral activity in transfected
cultured cells, and also reduced mice susceptibility to FMDV. By using different transcripts combinations, administration
schedules, and infecting routes and doses, we have demonstrated that these FMDV RNA transcripts protect suckling and
adult mice against lethal challenge with WNV. The protective activity induced by the transcripts was systemic and
dependent on the infection route and dose. These results confirm the antiviral potential of these synthetic RNAs for fighting
viruses of different families relevant for human and animal health.
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Introduction
West Nile virus (WNV), a flavivirus (Flaviviridae family), cycles
between mosquitoes and birds, but also infects a broad range of
mammals, including humans and horses [1,2]. After its first
description in 1937 [3], WNV had been associated with sporadic
outbreaks of meningoencephalitis in Africa, Europe, and the
Middle East until 1990’s. Since then, an increase in the number,
frequency and severity of West Nile disease (WND) cases in horses
and humans has been documented in Europe [1,2]. In 1999 WNV
emerged for the first time in the US [4] causing thousands of
infections among humans, horses, and birds. Although WNV
infections in humans and horses are mainly subclinical, clinically
apparent infections range from a febrile illness (West Nile fever) to
a neuroinvasive disease associated with a relatively high mortality
[1,2,5]. Currently, there is no vaccine approved for use in humans
and clinical treatment is only supportive [6]. Therefore, search for
antiviral compounds is a pivotal key for anti-WNV prophylaxis.
The innate immune response is a first line defense against
invading pathogens that depends on several sensors and signaling
pathways. The detection of viral products as pathogen-associated
molecular patterns (PAMPs), including single and double-stranded
RNAs, initiates a signaling cascade that leads to rapid antiviral
response, including the secretion of IFN-a and IFN-b, which have
well known antiviral, antiproliferative and immunomodulatory
functions [7].
WNV is highly sensitive to interferon. Administration of IFN to
a limited number of WNV-infected patients helped to reduce
disease complications in some of them, although in others failed to
do so [8–10]. As many other viruses, WNV has developed
different strategies to block the action IFN and thus, to evade the
host antiviral activity of IFN-stimulating genes, ISGs [6,11].
Different reports indicate that WNV non-structural proteins
contribute to control IFN-a/b signaling by different ways [6].
On the other hand, genetic polymorphism of the IFN-inducible
2959-oligoadenylate synthetases (OAS) has been involved in the
host innate resistance to WNV infection in horses [12], humans
[13] and mice [14]. RNA motifs in the 39 non-coding regions
(NCRs) of the hepatits C virus (Flaviviridae family) have been
described as IFN inducers when transfected into cultured cells and
mice [15,16], but a role of subgenomic RNAs from the 39 NCR of
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WNV in evading IFN response has also been recently reported
[17]. In addition, a genetic deficiency on the chemokine receptor
CCR5 has been associated with enhanced mortality in mice [18]
and humans [19]. Some IFN regulatory factors (IRFs) have been
implicated in systemic production of IFN-a, while other do not
have any appreciable effect [20] but, their role in protection
against WNV infection in vivo remains elusive [6,21]. Pretreatment
of cells with IFN inhibits flavivirus infection, but its effect is
markedly attenuated once viral replication has begun [22], as non-
structural viral proteins antagonize IFN effects [6]. Pretreatment
of rodents with IFN-a also reduced viral loads and mortality [23].
Recently, the ability of transcripts mimicking structural domains
in the 59 and 39 NCR of foot-and mouth disease virus (FMDV,
Picornaviridae family) genome to trigger IFN-b activity in cultured
cells has been reported [24]. Even more, when inoculated into
suckling mice, they were also able to trigger the innate immune
response and to reduce the susceptibility of the animals to FMDV
infection [24,25]. The level of the protective in vivo response was
dependent on the specific RNA and the dose administered and
was cross-protective against different FMDV serotypes [25].
Here, we have tested the capability of the 59NCR S and IRES
transcripts, proved to induce the highest protective effect in mice
against FMDV, to protect suckling and adult mice against
challenge with WNV. Our results confirm the wide prophylactic
potential of these molecules for viral control strategies.
Materials and Methods
Ethics Statement
All animals were handled in strict accordance with the
guidelines of the European Community 86/609/CEE at the
biosafety animal facilities of the Centro de Investigacio´n en
Sanidad Animal Of the Instituto Nacional de Investigacio´n
Agraraia y Alimentaria (CISA-INIA) The protocols were ap-
proved by the Committee on Ethics of Animal Experimentation of
INIA (permit numbers 2011–15 and 2011–35). Animals were
monitored twice daily and received water and food ad libitum. All
surgical manipulations were performed under anesthesia and
efforts were made to minimize suffering.
Virus and RNAs
West Nile virus NY-99 strain was propagated and titrated on
Vero cells as described [26–27]. RNA transcripts corresponding to
the S and IRES fragments (403 and 470 nucelotide-long,
respectively) of the 59 NCR of FMDV O1K and CS-8 genome,
respectively, were generated by in vitro transcription as described
[24].
Mice. Litters of 7 to 17 newborn (4–7 days-old) Swiss mice
were intraperitoneally (i.p.) inoculated with 100 mg of the
corresponding transcripts (either S or IRES), or poly (I:C) (Sigma),
in a final volume of 100 ml in PBS as described [24]. In the case of
RNA transcripts, 20 mg of lipofectin (Invitrogen), which has been
shown to have no influence in the protection induced by the
transcripts [25], was also added. After 24 h of RNA inoculation,
mice were infected with WNV, either i.p. (102 or 107 PFU/
mouse), or intracraneally, i.c. (10 or 102 PFU/mouse). As a
control, groups of mice were infected with the same amount of
virus that had been pre-incubated for 1 h at 37uC with a mice
neutralizing polyclonal anti-WNV sera pool (n-sera) [28]. Like-
wise, two groups of mice were i.c. or i.p. inoculated with PBS 24 h
before infection, and two additional good practice control groups
were inoculated with PBS by the same routes, but they were not
challenged with WNV. Additionally, litters of newborns were i.p.
inoculated as above with 100 mg of S, IRES, or an equimolar
mixture of both transcripts, and i.p. challenged with WNV
(102 PFU/mouse) 1 day before or 5 days after inoculation of the
RNAs. The mixture was not tested in the case of i.p. infection 5
days after treatment.
On the other hand, groups of 18 adult (6–8 weeks-old) Swiss
mice were i.p. inoculated with 200 mg of S or IRES transcripts
24 h or 48 h before, or 48 h after being i.p. infected with WNV
(105 PFU/mouse). A group of mice was pretreated with 200 mg of
poly (I:C) and a second one with PBS alone 24 h before infection.
Mice were bled 4, 8, and 24 h after treatment with the transcripts.
On day 3, 4 and 5 after infection, 2 randomly selected mice per
group were anesthetized, bled, euthanized, and their brains
collected and processed [26] for viral and immunological
determinations.
During the experiments mice were monitored twice daily and
received water and food ad libitum. Those mice showing clear signs
of disease were anesthetized and euthanized, as were all surviving
animals at the end of the experiment (4 weeks after infection). All
experiments with infectious virus were conducted in biosafety level
3 facilities.
Immunological and viral assays
Antibodies against WNV were measured by a validated ELISA
using WNV baculovirus expressed recombinant protein E as
antigen [29]. The positive cut off value was assigned using a
positive/negative (P/N) ratio $2, calculated by dividing the mean
absorbance of the test serum reacted on viral antigen by the
absorbance of the negative control serum on viral antigen. Virus
neutralization test (VNT) was performed, using serial serum
dilutions, in susceptible Vero cells as reported [30]. Titers were
calculated as the reciprocal of the serum dilution that completely
inhibited cytophatic effect at 1:20 or higher dilution.
Viral RNA was extracted from processed brains using a
NucleoSpin viral RNA isolation kit (Macherey-Nagel) and
quantified by real-time RT-PCR [26,31]. For RNA quantification
a standard curve was generated with previously titrated WNV
(106–1021 PFU), and samples were considered negative when
Ct$35, equivalent to 102 PFU/gram of tissue [26,32].
The levels of IFN-a in pools of sera from adult mice inoculated
with the different transcripts, the poly (I:C), or with PBS alone
were tested by ELISA using a commercial kit (PBL Interfer-
onSource). The limit of detection of IFN-a in serum samples in the
conditions assayed was 25 mg/ml, as determined in previous assays
(unpublished results). Antiviral activity of sera (1:1 dilution) was
also analyzed by a cytophatic effect inhibition test as described
[24,33], and expressed as the highest dilution of sera (log2) able to
suppress vesicular stomatitis virus (VSV)-induced cytophatic effect
on L-929 cells in 50% of the wells.
Statistical analyses
Kaplan-Meier survival curves were analysed by a logrank test
using GraphPad PRISM v.2.01 (GraphPad Software). Statistically
significant differences were considered at p,0.05. The median
survival time (MST) was calculated for every time and group of
inoculated mice.
Results
All suckling mice inoculated 24 h before infection, either with
the S, IRES, or poly (I:C), a synthetic double stranded RNA
homologue that has been shown to induce anti-viral activity in
suckling mice [23–25,34], and almost all (92.3%) of those in which
the virus was previously incubated with n-sera [28], survived to
intracraneal (i.c.) infection with the lowest dose of WNV tested,
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10 PFU/mouse (Fig. 1A). As expected, all mice in the PBS-
inoculated control group died of WND.
On the contrary, all suckling mice inoculated with S, IRES, poly
(I:C), or PBS 24 h before being intraperitoneally (i.p.) infected with
a very high dose (107 PFU) of WNV died 4 to 7 days later with
median survival time (MST) of 6 days for the S, IRES, and PBS,
and 5 days for the poly (I:C) (Fig. 1B). A high mortality (81.2%)
was also recorded in the control group in which the virus had been
incubated with n-sera before the infection, as only two animals
survived, although in this case the MST was higher (8, range 5–15
days, logrank test p,0.0029). No mortality was recorded in the
good practice groups, in which mice were i.c. or i.p. inoculated
with PBS but not infected (data not shown).
When newborn mice were i.c. infected with 100 PFU (Fig. 2 A,
C and E), a statistically significant high survival rate was observed
among those inoculated 24 h before with the RNA transcripts,
either the IRES (64%, p#0.0001), the S fragment (44%,
p#0.0208), or an equimolar mixture of both (90.9%,
p#0.0001), in comparison with the group of PBS-inoculated mice
(14.3%). Similar results were recorded in the control group, n-sera,
(81.8% of survivors, p#0.0001). In contrast, none of the 17 mice
inoculated with poly (I:C) survived to the infection.
Even superior protection rates were observed when the virus
was inoculated i.p. 24 h after treatment (Fig. 2 B, D and F), since
highest survival rates were recorded among mice pretreated with
the IRES (82.6%, p#0.0001), the S fragment (96.4%, p#0.0001),
or the mixture of both (100%, p#0.0007), as well as in the control
n-sera group (100%, p#0.0001), when compared with those
observed in mice treated with poly (I:C) (33.3% survival,
p#0.6272) or with PBS alone (28% survival).
The protective capacity of the S and IRES RNA transcripts,
and of an equimolar mixture of both, when administered 1 or 5
days after infection, was further compared with that observed
when they were inoculated 24 h before infection (Fig. 2). Some
protection (60% and 20%) was only observed when the IRES
transcript was administered 1 or 5 days after i.c. infection (Fig. 2A),
although these figures did not reach statistical significance
(p#0.089 and 0.405, respectively) when compared with the
control group. No protection was recorded in any other group
in which the transcripts were inoculated after infection, except for
a single mouse (11.2%) that survived to i.c infection 24 h after
treatment with the equimolar mixture of both RNAs (Fig. 2E). In
most cases, MST values were lower in mice treated 1 or 5 days
after infection than in those treated 24 h before. Likewise, these
values also tended to be lower in i.c. than in i.p. infected mice.
Since infection of adult mice is a more commonly used model
for WNV studies, the activity of these RNAs against WNV
infection was further analyze on them when administered before
or after infection (Figure 3). Animals inoculated with the IRES
48 h or 24 h before i.p. infection with 105 PFU of WNV showed
higher survival rates (58.3%, p#0.0741; and 41.7%, p#0.0457,
respectively) than those of the PBS-inoculated control group
(22.2%), but these figures dropped to 8.3% when treated 48 h
after infection (Fig. 3A). On the other hand, mice inoculated with
S transcript presented survival rates of 25% and 33.3% when the
transcripts were administered 48 h before or after infection,
respectively, but the rate raised to 83.3% (p#0.0001) when
inoculated 24 h before infection (Fig. 3B). A 66.6% (p#0.0135)
survival rate was also observed in the group of mice treated with
poly (I:C) 24 h before infection (Fig. 3C). Overall, MST values
were higher when the transcripts where administered 24 h before
infection than when inoculated 48 h before or after infection.
Analysis of IFN-a levels in sera from inoculated adult animals
(Fig. 4) showed that both transcripts elicited the highest levels at
8 h after inoculation and decreased to basal levels by 24 h
(Fig. 4A). Similar results were observed when antiviral activity of
these sera was tested in cell culture. In any case, IFN-a levels and
antiviral activity were always higher in IRES-treated adult mice
(Fig. 4B).
No specific anti-WNV antibodies were detected in the blood of
treated mice euthanized early after infection (3–5 days), while high
ELISA (median P/N = 8.5, range 7.5–11.5) and VNT (median 1/
320, range 1/80 to ,1/1280) titers were recorded in mice that
survived to the infection by the end of the experiment (20 d.p.i.),
regardless of the treatment received.
Over 55% (30/54) of the brains obtained from euthanized mice
3–5 d.p.i. resulted positive by RT-PCR for WNV-RNA with
variable titers (average 1.26105 genomic equivalents/gram of
tissue, range 26102–1.76106). These figures rose to 85.7% (12/
14) when brains from mice that died of WND 8–9 d.p.i. were
analyzed (average 3.36106 genomic equivalents/gram of tissue,
range 46102–2.96107); however, the limited number of samples
analyzed did not allow a proper comparison between the different
groups.
Figure 1. Survival rates of suckling mice treated with the different transcripts 24 h before infection with WNV. Mice were i.p.
inoculated with the corresponding transcripts (either S or IRES), or with poly (I:C), or PBS alone 24 h before being i.c. infected with 10 PFU/mouse (A),
or i.p. with 107 PFU/mouse (B), as described in Materials and Methods. As a control, a group (Ab) of mice was infected with the same amount of virus
previously incubated with a neutralizing polyclonal anti-WNV sera pool.
doi:10.1371/journal.pone.0049494.g001
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Figure 2. Survival rates of WNV infected suckling mice treated with the different transcripts at various time intervals. Mice were i.p.
inoculated with the corresponding transcripts, either the IRES (A and B), the S fragment (C and D), or an equimolar mixture of both, IRES+S (E and F) 1
day before (21), or 1 (+1) or 5 (+5) days after i.c. (A, C and E) or i.p. (B, D and F) infection with 102 PFU/mouse of WNV, as described in Materials and
Methods. Survival rates of mice inoculated with poly (I:C), PBS alone, or virus that had been previously incubated with a neutralizing polyclonal anti-
WNV sera pool (Ab), 24 h before infection are shown in each panel for comparison.
doi:10.1371/journal.pone.0049494.g002
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Figure 3. Survival rates of WNV infected adult mice inoculated with the different transcripts at various time intervals. Mice were i.p.
inoculated with the corresponding transcripts, either the IRES (A), the S fragment (B), 1 (21) and 2 (22) days before and 2 (+2) days after i.p. infection
with 105 PFU/mouse of WNV, as described in Materials and Methods. Survival rates of mice inoculated with PBS alone or with poly (I:C) 24 h before
infection are shown for comparison (C).
doi:10.1371/journal.pone.0049494.g003
Protection against WNV by RNA Transcripts
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Discussion
The capability of non-infectious in vitro transcribed RNAs,
mimicking structural domains of the NCRs of the picornavirus
FMDV, to trigger the immune response in porcine cultured cells
and mice [24], and to induce protection against challenge of
suckling mice with FMDV homologous and heterologous strains
have been reported [25]. Here, we have assessed the potential of
two of these transcripts (the IRES and S fragments) to protect
against infection with an important zoonotic unrelated virus, the
flavivirus WNV, in both suckling and adult mice.
Protection against WNV infection was achieved in suckling
mice after treatment with the two transcripts and the survival rates
depended on the infecting viral dose, as previously shown for
FMDV [25], and also on the infection route. Accordingly, while
no protection was observed in any of the experimental groups in
which mice were i.p. infected with a very high dose (107 PFU/
mouse) of WNV, a full protection was observed in animals i.c.
infected with the lower dose administered (10 PFU/mouse),
except in those of the control group that were inoculated with
PBS alone whose showed mortality rates close to 100%, as
previously reported in non-treated WNV-infected suckling mice
[28].
Though the viral load inoculated by different species of
mosquitoes varies (101–106 PFU), most of them inoculate around
102 PFU directly into the blood when feeding on mice [35]. Our
results indicate that, when 102 PFU of WNV were used to i.c.
infect suckling mice, relatively high protection rates were observed
among those animals inoculated with the IRES, the S, or the
mixture of both fragments, 24 h prior to the infection (64%, 44%,
and 90.9%, respectively), which were lower than that of the
control group (81.8%) inoculated with virus that had been
previously incubated with a neutralizing anti-WNV polyclonal
sera pool (n-sera). In any case, these survival rates were
significantly higher than those recorded among the poly (I:C)
(0%) and PBS (14.3%) inoculated control mice. On the other
hand, MST in the PBS-inoculated mice group, although lower,
was not markedly different than that of the remaining groups.
Even higher survival rates were observed in mice treated with
the RNA transcripts 24 h before infection when the same infecting
dose (102 PFU/mouse) was administered by i.p. route instead of
i.c. (82.6%, 96.4% and 100% for the IRES, the S fragment and
the mixture of both, respectively). A full protection was also
achieved in the control n-sera group. Again, these rates were
significantly higher than those of the poly (I:C) (33.3%) and PBS
(28%) groups. Despite that no marked differences in survival rates
between treated and untreated mice infected with FMDV have
been observed [25], a trend to lower MST was noticed in treated
WNV-infected animals. This fact could be due to the different in
vivo kinetics and pathogenicity of FMDV and WNV in newborn
mice, as MST of 1.9 [25] and around 8.5 [28, and present report]
days were respectively recorded in PBS-inoculated suckling mice.
The finding that i.p. treatment with the FMDV RNAs protected
against direct infection into the brain of suckling mice indicates
that the response induced was systemic. On the other hand, our
results also showed that the route of viral inoculation is also
important, as protection was higher after i.p. infection. WNV
initially replicates at the inoculation site and then traffics to the
lymph nodes and blood stream from where it reaches the spleen
and kidneys and, finally, penetrates the CNS [11], where it is
capable to directly infect neurons [21,36]. Thus, in some cases, i.c.
infection could probably allow enough viral replication in the
brain before the level and efficacy of the IFN response induced by
the transcripts has had time to stop disease progression.
When experiments were conducted using adult mice, similar
results were observed, as 41.7% and 83.3% survival rates were
recorded, respectively, among mice inoculated with the IRES or
the S transcripts 24 h before infection with 105 PFU of WNV, in
comparison with the 22.2% survival rate observed in PBS-treated
mice, which is similar to that previously documented in untreated
adult mice [26,36–38]. In this case, confirming previous data [23],
protection was also obtained in adult mice after poly (I:C)
administration (66.6%).
A previous study [25] showed that the high protection observed
in suckling mice after FMDV challenge when the IRES (86%) and
S (100%) transcripts were inoculated 24 h before FMDV infection,
decreased when they were administered either 72 h (0% and 36%,
respectively) or 48 h (56% and 50%, respectively) before
challenge. Here, these results were confirmed, as little protection
was observed in suckling mice upon inoculation with the
Figure 4. FMDV NCR transcripts trigger innate immunity in adult mice. Groups of adult mice were i.p. inoculated with 200 mg of the IRES,
the S fragment, poly (I:C), or PBS. Levels of IFN-awere measured for each group of mice in pools of sera collected at 4, 8 or 24 h, by ELISA (A), cut-off
25 pg/ml, and the antiviral activity was determined (B) on L929 cells, starting from 1:1 sera dilution, as described in Materials and Methods.
doi:10.1371/journal.pone.0049494.g004
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transcripts 1 or 5 days after WNV infection when compared with
that observed when administered 24 h before. The only noticeable
exception (60% and 20% protection) was observed upon
administration of the IRES 1 or 5 days after infection. These
results remark that the potential prophylactic activity of these
molecules has a quite narrow window. On the other hand, both
transcripts protected adult mice when administered 1 day before
WNV infection (42% and 83%), but some level of protection was
also observed when administered 2 days before (58% and 25%,
respectively) or after (8% and 33%, respectively) infection. The
levels of IFN-a and antiviral activity in cultured cells detected in
sera from treated adult mice supports these findings, since both
RNAs induced a peak of IFN-a at 8 h post-inoculation that
declined to basal levels 24 h later.
These observations are in accordance to those previously
documented after administration of IFN, or IFN derivatives,
whose activity is usually effective only when triggered previous or
very close to the infection, because resistance to its effects once the
infection has been established has been reported in cell culture,
animal models and humans [8,9,22]. For instance, prophylactic
treatment with IFN-a administered once daily for 7 days, starting
24 h before WNV infection, completely prevented death in adult
mice, but treatment efficacy was strongly reduced (30% survival)
when the drug administration was initiated 4 to 6 h before
infection and maintained during 5 days [23]. Nevertheless, a case
in which substantial beneficial effects were observed when IFN
treatment was started in a patient with WN meningoencephalitis 3
weeks after disease presentation has been documented [10].
Adult mice that survived to the infection showed ELISA and
VNT values similar to that previously described [28], but no
differences were observed between the titers of mice treated with
PBS or with the transcripts, suggesting that the level of viral
replication induces a similar antibody response in all surviving
mice.
As previously observed in WNV infected adult mice
[26,32,36,37], WNV-RNA was detected at quite variable levels
in more than half of the mice euthanized 3–5 d.p.i, but no
apparent differences were observed as a consequence of the
inoculum (RNA transcripts or PBS) used or the inoculation
schedule (before or after infection). However, it should be noted
that only a small number of samples was analyzed in each group
and, thus, further experiments are needed for a proper analysis.
Our results document that both RNA transcripts tested protect
against WNV infection, and even though their activity window is
narrow, they are helpful in activating the innate response against
the infection. Their potential therapeutic use would benefit from
further studies aimed to optimization of parameters such as
delivery, dose range or route of administration, taking advantage
of newly developed RNA-based technology [39,40], The immu-
nomodulatory effect of the IFN induced by these transcripts also
suggests that they may be useful co-adjuvant molecules and,
therefore, further analyses should be conducted to address this
point. Nevertheless, the role played by the different cellular
compounds involved in triggering the IFN response after
administration of the RNAs used here remains to be elucidated.
In summary, our results extend the range of the in vivo antiviral
activity raised by FMDV NCR RNA transcripts and remark their
potential for prophylactic treatment against a variety of viruses.
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